Pfizer Lyme Disease Vaccine: 70% Efficacy & FDA Approval Path

Pfizer is moving forward with plans to seek regulatory approval for its Lyme disease vaccine candidate, despite the fact that the Phase 3 trial did not meet its pre-determined statistical goals. The announcement, made on March 23, 2026, comes as topline results from the VALOR trial revealed an efficacy rate of over 70% in preventing Lyme disease in individuals aged five years and above.

The trial, dubbed “Vaccine Against Lyme for Outdoor Recreationists,” demonstrated an efficacy of 73.2% from 28 days post-dose 4 and 74.8% from one day post-dose 4 in reducing confirmed Lyme disease cases compared to a placebo group. However, researchers noted that fewer Lyme disease cases were accrued during the study period than anticipated, leading to the failure to meet the primary statistical criterion. Despite this, Pfizer expressed confidence in the vaccine’s potential, citing the clinically meaningful efficacy observed.

A Long-Awaited Vaccine in Development

The development of a human vaccine for Lyme disease has been a decades-long pursuit. SmithKline Beecham previously developed a Lyme disease vaccine, LYMErix, which was approved by the FDA in 1998 but withdrawn from the market in 2002 due to low demand and public concerns about potential side effects. The current effort, a collaboration between Pfizer and Valneva SE, represents a renewed attempt to address the growing public health concern posed by Lyme disease, a tick-borne illness that can cause debilitating symptoms if left untreated.

Valneva estimates that the Lyme disease shot could reach annual peak sales exceeding $1 billion. While this figure doesn’t position the vaccine as a blockbuster for Pfizer – the company anticipates overall revenue of around $60 billion this year, with its COVID-19 vaccine contributing over $5 billion – it represents a significant opportunity to fill a critical gap in preventative healthcare. Pfizer had previously highlighted the Lyme vaccine results as a key catalyst for the year.

Regulatory Path Forward and Potential Impact

Pfizer intends to submit the data from the VALOR trial to regulatory authorities, including the U.S. Food and Drug Administration (FDA), for review. The FDA recently proposed a framework to expedite the approval of gene therapies for rare diseases, signaling a willingness to adapt its processes to accelerate access to innovative treatments. While this framework doesn’t directly apply to the Lyme vaccine, it reflects a broader trend toward streamlining regulatory pathways for promising medical interventions.

The vaccine candidate, PF-07307405 (formerly known as VLA15), is a 6-valent OspA-based vaccine. OspA is a surface protein found on the Lyme disease-causing bacteria, Borrelia burgdorferi. The vaccine works by stimulating the immune system to produce antibodies against OspA, thereby protecting against infection. The trial results also indicated that the vaccine was well-tolerated, with no significant safety concerns identified during the analysis.

What to Watch For

The coming months will be crucial as Pfizer prepares and submits its application to the FDA. The agency’s review will determine whether the observed efficacy, despite not meeting the initial statistical benchmark, is sufficient for approval. Analysts will be closely watching for the FDA’s response and any potential requests for additional data. Beyond regulatory approval, the success of the vaccine will depend on factors such as public acceptance, insurance coverage, and the implementation of effective vaccination programs, particularly in regions with high Lyme disease incidence. The potential for a widely available and effective Lyme disease vaccine offers a significant step forward in protecting public health against this increasingly prevalent illness.